Business / Finance

RSS

Thermedical closes $1.5 million in Series A funding

Thermedical, a privately held company developing proprietary thermal therapy equipment for numerous clinical conditions, today announced that it closed $1.5 million in Series A funding with a private investor, Samuel H. Maslak, Sc.D.

21 Mar 2012

GeoVax enters into definitive agreements to sell Series A convertible preferred stock

GeoVax Labs, Inc., an Atlanta-based biopharmaceutical firm developing vaccines to prevent and fight Human Immunodeficiency Virus (HIV) infections, announced today that it has entered into definitive agreements with certain institutional investors, pursuant to which the Company has agreed to sell shares of its Series A convertible preferred stock at an aggregate purchase price of approximately $2.2 million and Series A warrants to purchase up to an aggregate of 2,933,333 shares of GeoVax common stock with an exercise price of $1.00 per share and a term of five years.

21 Mar 2012

Enzo Life Sciences, Cosmo Bio expand business arrangement

Enzo Biochem Inc. announced today an expanded business arrangement between its wholly owned subsidiary, Enzo Life Sciences, and Tokyo-based Cosmo Bio Co., Ltd..

21 Mar 2012

ISCO fourth quarter revenue increases 110% to $1.1 million

International Stem Cell Corporation today announced year-end financial results for the year ended December 31, 2011.

21 Mar 2012

PSG closes acquisition of Artemetrx

Pharmaceutical Strategies Group, LLC, America's largest independent pharmacy benefits consulting firm, has closed on its acquisition of Artemetrx Health Resources, the company announced today.

21 Mar 2012

IGI fourth quarter total revenues increase 21% to $2.1M

IGI Laboratories, Inc., a New Jersey based topical generic drug development and manufacturing company, provided its financial results for the fourth quarter and year ended December 31, 2011.

21 Mar 2012

Acelrx fourth quarter net loss increases to $6.4 million

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today reported financial results for the fourth quarter and year ended December 31, 2011.

20 Mar 2012

Tobii completes USD $21 million funding round

Tobii Technology, the global leader in eye tracking and gaze interaction, announced today that it has closed a USD $21M funding round. New investor Intel Capital joins existing investors Amadeus Capital, Investor Growth Capital and Northzone Ventures.

20 Mar 2012

RBC Life Sciences 2011 consolidated net sales increases to $28.4 million

RBC Life Sciences, Inc., a provider of proprietary nutritional supplements, and wound care and pain management products, today reported consolidated net sales of $28.4 million for the year ended December 31, 2011, a 1% increase over 2010 consolidated net sales of $28.2 million.

19 Mar 2012

CoActiv Medical, Capital X-Ray enter distribution agreement

CoActiv Medical, the PACS, RIS and cloud-based digital archiving innovator, announces a distribution agreement with Capital X-Ray, the largest independent x-ray dealer in the Southeast. Under the new agreement, CXR will distribute the complete CoActiv product line in Mississippi, Alabama, Georgia and the Florida panhandle.

19 Mar 2012

QRxPharma, Actavis enter License and Option Agreement

QRxPharma Limited announced today execution of its License and Option Agreement with Actavis, Inc. which finalised the legal terms and conditions to commercialise MoxDuo IR in the US acute pain marketplace. The LOA completion follows a 20 December 2011 signing of a binding Letter of Intent secured by a US$6 million non-refundable upfront signing fee to QRxPharma.

19 Mar 2012

XTL Biopharmaceuticals completes $2.4 million private placement of securities

XTL Biopharmaceuticals announced yesterday, March 18, 2012, it successfully completed a private placement of securities with foreign as well as Israeli institutional and private investors for a total of $2.4 million (NIS 9.1 million).

19 Mar 2012

inVentiv Health enters agreement to acquire Kforce Clinical Research

inVentiv Health, Inc., offering best-in-class clinical, commercial and consulting services to the healthcare industry, today announced that it has signed a definitive agreement to acquire Kforce Clinical Research, Inc. ("KCR"), a provider of functional outsourcing solutions to pharmaceutical, biotech and medical device companies, from Kforce Inc. for $50 million in cash.

19 Mar 2012

Covidien to acquire superDimension

Covidien, a leading global provider of healthcare products, today announced a definitive agreement to acquire superDimension, Ltd., a private company based in Herzliya, Israel, that develops minimally invasive interventional pulmonology devices.

19 Mar 2012

China Botanic first quarter net sales increase 24.4% to $28.1M

China Botanic Pharmaceutical Inc., a developer, manufacturer and distributor of botanical products, bio-pharmaceuticals and Traditional Chinese Medicines in China, today announced financial results for the three months ended January 31, 2012.

19 Mar 2012

RBCC's new agreement with n3D could help develop stem-cell therapies

As global demand for innovative new stem-cell therapies grows by the day, Rainbow BioSciences' new agreement with n3D Biosciences could help to bring these therapies to market faster than ever before.

19 Mar 2012

Kanghui fourth quarter total net revenue increases 33.6% to RMB96.6M

China Kanghui Holdings, a leading domestic developer, manufacturer and marketer of orthopedic implants in China, today announced its unaudited financial results for the fourth quarter and full year 2011.

19 Mar 2012

Sanofi enters definitive agreement to acquire Pluromed

Sanofi and Pluromed Inc. announced today that they have entered into a definitive agreement under which Sanofi is to acquire Pluromed Inc., a medical device company based in Woburn, Massachusetts.

17 Mar 2012

Kensey Nash to resolve Angio-Seal license disputes with St. Jude Medical

Kensey Nash Corporation today announced that the Company has entered into a settlement agreement with St. Jude Medical which resolves all disputes between the two companies relating to the Angio-Seal vascular closure device licenses, as well as other related claims.

17 Mar 2012

OncoGenex prices underwritten public offering of 4,165,000 shares of common stock

OncoGenex Pharmaceuticals, Inc. today announced that it has priced an underwritten public offering of 4,165,000 shares of its common stock at a purchase price of $12.00 per share.

17 Mar 2012